MADE SIMPLE

One, two, or three pathways?

More receptors does not automatically mean “better.” Each mechanism changes the benefit-risk picture.

GLP-1GIPGCG

Semaglutide

Single agonist

GLP-1GIPGCG

Tirzepatide

Dual agonist

Results from controlled trials cannot be assumed for unregulated products. For educational purposes only. Not medical advice, diagnosis, treatment, or prescribing guidance. Research and regulatory information can change over time.

Next: peptide math